nuclear pore associated protein 1 pseudogene 7Genealiases: []
Q-omics provides the consensus-scored NPAP1P7 profile across patient tissues and cancer cell-line models. NPAP1P7 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, NPAP1P7 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, NPAP1P7 RNA expression shows 5,583 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, and STAD as cancer lineages where NPAP1P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPAP1P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPAP1P7 survival associations across molecular data types. NPAP1P7 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPAP1P7 RNA expression–survival associations across cancer types. High NPAP1P7 expression shows unfavorable associations in UCS, BLCA, THCA, KIRP, LUSC and GBM. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for NPAP1P7 RNA expression.
This table summarizes NPAP1P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for NPAP1P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPAP1P7 shows lower tumor expression in STAD and higher tumor expression in KIRP. The STAD box plot shows higher NPAP1P7 RNA expression in normal versus tumor tissue (log2 FC = −0.014, t-test p = .040).
This table shows molecular features associated with NPAP1P7 in patient tissues and cancer cell lines. In patient samples, NPAP1P7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
